Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.

被引：2

作者：

Yalcin, Suayib

Dane, Faysal

Oksuzoglu, Berna

Yildirim, Nuriye

Isikdogan, Abdurrahman

Ozkan, Metin

Demirag, Guzin

Coskun, Hasan Senol

Karabulut, Bulent

Evrensel, Turkkan

Ustaoglu, Mehmet Ali

Ozdemir, Feyyaz

Turna, Hande

Yavuzsen, Tugba

Aykan, Faruk

Sevinc, Alper

Akbulut, Hakan

Yuce, Deniz

Hayran, Mutlu

Kilickap, Saadettin

机构：

[1] Hacettepe Univ, Ankara, Turkey

[2] Marmara Univ, Istanbul, Turkey

[3] Dr A Y Ankara Oncol Training & Res Hosp, Ankara, Turkey

[4] Ankara Numune Training & Res Hosp, Ankara, Turkey

[5] Dicle Univ, Med Sch, Diyarbakir, Turkey

[6] Erciyes Univ, Kayseri, Turkey

[7] Ondokuzmayis Univ Med Oncol, Samsun, Turkey

[8] Akdeniz Univ, Antalya, Turkey

[9] Ege Univ, Izmir, Turkey

[10] Uludag Univ, Pittsburgh, PA USA

[11] Lutfi Kirdar Hosp, Istanbul, Turkey

[12] Karadeniz Tech Univ, Fac Med, Trabzon, Turkey

[13] Istanbul Univ, Cerrahpasa Sch Med, Istanbul, Turkey

[14] Dokuz Eylul Univ, Oncol Inst, Izmir, Turkey

[15] Istanbul Univ, Inst Oncol, Istanbul, Turkey

[16] Gaziantep Univ, Gaziantep, Turkey

[17] Hacettepe Univ, Canc Inst, Ankara, Turkey

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期

关键词：

D O I：

10.1200/JCO.2018.36.4_suppl.346

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

346

引用

页数：1

共 50 条

[41] Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer
Brodowicz, T
Wolfram, RM
Köstler, WJ
Tomek, S
Vaclavik, I
Steger, GG
Teleky, B
Függer, R
Jakesz, R
Zielinski, CC
ANTI-CANCER DRUGS, 2000, 11 (08) : 623 - 628
[42] A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
Hu, Zishuo Ian
Bendell, Johanna C.
Bullock, Andrea
LoConte, Noelle K.
Hatoum, Hassan
Ritch, Paul
Hool, Hugo
Leach, Joseph W.
Sanchez, James
Sohal, Davendra P. S.
Strickler, John
Patel, Ravindranath
Wang-Gillam, Andrea
Firdaus, Irfan
Yu, Kenneth H.
Kapoun, Ann M.
Holmgren, Eric
Zhou, Lei
Dupont, Jakob
Picozzi, Vincent
Sahai, Vaibhav
O'Reilly, Eileen M.
CANCER MEDICINE, 2019, 8 (11): : 5148 - 5157
[43] A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer.
Gao, Chuntao
Chen, Xingyun
Hao, Jihui
Zhang, Yanqiao
Qu, Xiujuan
Zhang, Jingdong
Wu, Heshui
Sun, Meili
Zha, Yong
Wang, Junbin
Wang, Yusheng
Li, Zhihua
Cheng, Ying
Liu, Yanping
Miao, Niu
Xie, Yijiao
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[44] A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)
Ozaka, Masato
Nakachi, Kohei
Kobayashi, Satoshi
Ohba, Akihiro
Imaoka, Hiroshi
Terashima, Takeshi
Ishii, Hiroshi
Mizusawa, Junki
Katayama, Hiroshi
Kataoka, Tomoko
Okusaka, Takuji
Ikeda, Masafumi
Sasahira, Naoki
Miwa, Haruo
Mizukoshi, Eishiro
Okano, Naohiro
Mizuno, Nobumasa
Yamamoto, Tomohisa
Komatsu, Yoshito
Todaka, Akiko
Kamata, Ken
Furukawa, Masayuki
Fujimori, Nao
Katanuma, Akio
Takayama, Yukiko
Tsumura, Hidetaka
Fukuda, Haruhiko
Ueno, Makoto
Furuse, Junji
EUROPEAN JOURNAL OF CANCER, 2023, 181 : 135 - 144
[45] A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)
Shen, Lin
Yu, Xianjun
Hao, Jihui
Wang, Liwei
Pan, Hongming
Han, Guohong
Xu, Jian-Ming
Zhang, Yanqiao
Yang, Shujun
Chen, Jia
Ying, Jieer
Dai, Guanghai
Li, Mingyu
Begic, Damir
Lu, Brian D.
Xu, Ruihua
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[46] PHASE II STUDY OF GEMCITABINE + TH-302 VS GEMCITABINE ALONE IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC PANCREATIC CANCER
Ryan, D.
Reddy, S.
Bahary, N.
Uronis, H.
Sigal, D. S.
Cohn, Allen
Schelman, W. R.
Chiorean, E. G.
Rosen, P. J.
Ulrich, B.
Dragovich, T.
Del Prete, S.
Rarick, M.
Eng, C.
Kroll, S.
ANNALS OF ONCOLOGY, 2012, 23 : 8 - 8
[47] Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss
Lisa Blaydorn
Julia Beck
Kirsten Bornemann-Kolatzki
Howard Urnovitz
Ekkhard Schütz
Vivek Khemka
Investigational New Drugs, 2019, 37 : 797 - 797
[48] Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer
Ramanathan, Ramesh K.
Lee, Peter
Seng, John E.
Anthony, Stephen Patrick
Rosen, Peter J.
Mena, Raul R.
Picozzi, Vincent J.
Sachdev, Jasgit C.
Larson, Tim
Korn, Ronald
Jameson, Gayle S.
Stoll, Amy C.
Von Hoff, Daniel D.
Leach, Joseph W.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[49] Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer
Ramanathan, Ramesh K.
Lee, Peter
Leach, Joseph W.
Anthony, Stephen Patrick
Weiss, Glen J.
Rosen, Peter J.
Picozzi, Vincent J.
Sachdev, Jasgit C.
Larson, Tim
Korn, Ronald
Hu, Chengcheng
Jameson, Gayle S.
Stoll, Amy C.
Von Hoff, Daniel D.
Seng, John E.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[50] A randomized phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer.
Stathopoulos, GP
Aravantinos, G
Syrigos, K
Kalbakis, K
Karvounis, N
Papakotoulas, P
Boukovinas, J
Potamianou, A
Polyzos, A
Christophilakis, CH
Georgoulias, V
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S

← 1 2 3 4 5 →